- Home
- AAMI vs XENE Comparison
AAMI vs XENE Comparison
Compare AAMI & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAMI | XENE |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.7B |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AAMI | XENE |
|---|---|---|
| Price | $97.07 | $40.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 18 |
| Target Price | ★ $99.33 | $71.69 |
| AVG Volume (30 Days) | 397.8K | ★ 1.2M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.44 | N/A |
| Revenue | ★ $426,600,000.00 | $311,000.00 |
| Revenue This Year | $37.22 | N/A |
| Revenue Next Year | $14.74 | $1,367.80 |
| P/E Ratio | $39.98 | ★ N/A |
| Revenue Growth | ★ 2.25 | N/A |
| 52 Week Low | $41.47 | $33.38 |
| 52 Week High | $98.52 | $72.66 |
Technical Indicators
Market Signals| Indicator | AAMI | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 62.59 | 58.71 |
| Support Level | $88.05 | $40.67 |
| Resistance Level | N/A | $43.67 |
| Average True Range (ATR) | 3.88 | 1.33 |
| MACD | 0.51 | 0.98 |
| Stochastic Oscillator | 91.27 | 90.18 |
Price Performance
Historical ComparisonAbout AAMI Acadian Asset Management Inc.
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.